Cover Image
市場調查報告書

再生醫療的全球市場:各技術 (細胞治療,基因治療,組織工程,小分子及生技藥品) 、各材質及各用途 - 市場機會分析及產業預測

Regenerative Medicines Market by technology, Material - Global Opportunity Analysis and Industry Forecast, 2015 - 2022

出版商 Allied Market Research 商品編碼 370276
出版日期 內容資訊 英文 145 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
再生醫療的全球市場:各技術 (細胞治療,基因治療,組織工程,小分子及生技藥品) 、各材質及各用途 - 市場機會分析及產業預測 Regenerative Medicines Market by technology, Material - Global Opportunity Analysis and Industry Forecast, 2015 - 2022
出版日期: 2016年08月01日 內容資訊: 英文 145 Pages
簡介

全球再生醫療市場由於幹細胞技術的登場和奈米技術,慢性疾病的罹患率上升,監測設備和外科技術的創新等要素而促進了成長。預測細胞治療雖然壟斷市場,但小分子及生技藥品市場區隔在2016∼2022年將以年複合成長率34.2%的速度擴大。

本報告提供全球再生醫療市場相關調查,彙整市場上各技術,各材質,用途趨勢與各地區趨勢,2014∼2022年的預測,及加入此市場的主要企業簡介等資料。

第1章 簡介

第2章 摘要整理

第3章 市場概要

  • 市場定義和範圍
  • 主要調查結果
  • 波特五力分析
  • 市場趨勢
    • 促進要素
    • 阻礙要素
    • 機會

第4章 各產品市場

  • 概要
  • 細胞治療
  • 基因治療
  • 組織工程
  • 小分子及生技藥品

第5章 各材料市場

  • 概要
  • 合成材料
  • 生物學的來歷的材料
  • 基因改造材料
  • 醫藥品

第6章 各用途市場

  • 概要
  • 心血管
  • 腫瘤科
  • 皮膚科
  • 肌肉骨骼
  • 外傷治療
  • 眼科
  • 神經科
  • 其他

第7章 各地區市場

  • 概要
  • 北美
  • 歐洲
  • 亞太地區
  • 南美·中東·非洲

第7章 企業簡介

  • Integra Lifesciences Corporation
  • Stryker Corporation
  • Acelity Holdings, Inc. (LifeCell Corporation)
  • Organogenesis Inc. (Advanced Biohealing)
  • Arteriocyte Medical Systems, Inc.
  • Athersys, Inc.
  • U.S. Stem Cell, Inc. (Bioheart, Inc.)
  • Zimmer Biomet Holdings, Inc. (Zimmer)
  • CryoLife, Inc.
  • Medtronic plc

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: LI 16391

Regenerative medicines have the unique ability to repair, replace and regenerate tissues and organs, affected due to some injury, disease or due to natural aging process. These medicines are capable of restoring the functionality of cells and tissues. These medicines find applicability in wide range of degenerative disorders including dermatology, neurodegenerative diseases, cardiovascular and orthopedic applications. Researchers are engaged in developing technologies based on biologics, genes, somatic as well as stem cells.

The factors driving growth of this market include advancements in stem cell therapy, significance of nanotechnology and increasing incidences of degenerative diseases. Stem cells have unique ability of proliferation and differentiation. These cells can differentiate into any cell lineage. This distinctive characteristic of stem cells has made them of significant importance in this field. Additionally, the utilization of nano-materials in wound care, drug delivery and immunomodulation is opening growth avenues for the regenerative medicine market. However, the stringent regulations and the high cost of treatment act as hindrance for the progress of this market. The increasing focus on stem cells, their applications and the emerging economies would all contribute to the growth of this market. The developing nations are adopting technological advancements at a rapid pace, which would aid in the expansion of this market throughout the globe.

Reasons for Doing Study

Presently, majority of treatments available for degenerative or life-threatening diseases do not provide a cure or are palliative. Several others just postpone the progress of the disease. In contrary, regenerative medicines have the capability to replace or regenerate the tissues and organs suffering from injury or disease. These medicines find application in wide range of degenerative disorders and has proven to be efficient in many of the applications. Therefore, in-depth study of this market would provide an overall understanding of the market along with the growth opportunities in this field. The insights on applicable technologies and geographies would help the stakeholders in formulating strategic decisions.

Regenerative Medicine Market Analysis by Technology

On the basis of technology used, this market is segmented into small molecules & biologics, gene therapy and cell therapy. The small molecules and biologics segment have the largest contribution among all other technologies used for creating regenerative products. This is due to their efficiency in penetrating to internal membranes of the internal organs. However, gene therapies are expected to be the fastest emerging technology, growing at a CAGR of 28.6% during 2014-2020. The key reason for the growth of this technology can be attributed to the tremendous potential of gene therapy in minimizing immune rejections, which commonly occur after transplantations.

Regenerative Medicine Market Analysis by Applications

Based on its applications, this market can be classified into dermatology, cardiovascular, orthopaedic, central nervous system (CNS), dental and others. The cardiovascular applications have commercialized products as well as ongoing trials. Therefore, this is the largest revenue regenerating application market. However, due to immense focus on clinical studies in CNS disorders, this market is expected to gain momentum by 2020. The market for CNS is the fastest growing application segment at a CAGR of 30.8% during 2014-2020. This is due to recent approvals for a regenerative product intended to treat multiple sclerosis and increasing number of clinical trials for neurodegenerative disorders.

Regenerative Medicine Market Analysis by Geography

On the basis of geography, this market can be classified into North America, Europe, Asia-Pacific and LAMEA. Currently, North America dominates the global market due to heavy investment in development of regenerative products as well as more number of commercialized products. However, the growing focus on research and development in Japan and South Korea makes Asia-Pacific the fastest growing region at a CAGR of 30.9% during 2014-2020.

Competitive Analysis

The key companies included in the report are Shire Pharmaceuticals, Advanced Cell Technology, Genzyme, Athersys Inc., Kinetic Concepts, Inc., NuVasive, Stem Cells, Inc., Cytori Therapeutics, Inc., Cytomedix Inc. and Mesoblast Ltd. The primary strategy adopted by these companies is approval. These approvals are required prior to the initiation of clinical trials, during trials and for commercialization of these therapies. Secondly, some of the companies mentioned in the report acquired other company to enter into the field of regenerative medicines. These companies also entered in collaboration with research institutes or universities for conducting research and studies. The companies fostered these strategies to develop effective medications and therapies, thereby leading to product commercialization.

High Level Analysis

The report provides an analysis of the overall industrial scenario of regenerative medicines using Porter's five forces model. The analysis advocates moderate bargaining power of suppliers and low bargaining power of buyers. The presence of limited number of suppliers increases their authority, whereas the prevailing stringent regulations lower their bargaining power. Therefore, the overall bargaining power of suppliers is moderate. On the other hand, the high cost of switching reduces the bargaining power of buyers. Furthermore, the inefficiency of the substitutes available for regenerative medicines lowers the threat from substitute in this market. The value chain analysis helps in assessment of primary and support activities for regenerative medicines.

Regenerative Medicines

KEY BENEFITS

  • The report provides an evaluation of drivers and restraints in this market, which would affect its growth. An assessment of opportunities is given to understand the growth avenues
  • The technology segment helps in understanding the present technologies used in this market
  • The application segment describes the availability of product based on type of diseases and discusses the ongoing studies for other disorders
  • The segmentation based on geography helps in analyzing advancements in regenerative medicine market throughout the globe
  • The projections in the report are made by analyzing the current market trends and future market potential for the period of 2013-2020
  • The key strategies adopted by the market players are discussed to provide an insight on the winning approaches followed by the companies
  • Porter's five forces analysis is used to assess the present industrial scenario to help stakeholders in making decisive moves

KEY DELIVERABLES

  • The global regenerative medicine market is segmented based on technology, application and geography.

KEY MARKET SEGMENTS

  • MARKET BY TECHNOLOGY
  • Small molecules and Biologics
  • Gene therapy
  • Cell therapy
  • MARKET BY APPLICATION
  • Dermatology
  • Cardiovascular
  • CNS
  • Orthopedic
  • Dental
  • Others
  • Autoimmune disorders
  • Muscle regeneration
  • Ocular diseases
  • MARKET BY GEOGRAPHY
  • North America
  • Europe
  • Asia-Pacific
  • LAMEA

Table of Contents

CHAPTER 1. INTRODUCTION

  • 1.1 Report description
  • 1.2 Reasons for doing study
  • 1.3 Key deliverables
  • 1.4 Key benefits
  • 1.5 Key audiences
  • 1.6 Research methodology
    • 1.6.1 Secondary research
    • 1.6.2 Primary research
    • 1.6.3 Analyst tools and models

CHAPTER 2. EXECUTIVE SUMMARY

  • 2.1 CXO perspective
  • 2.2 Market beyond: what to expect by 2025
    • 2.2.1 Moderate Growth Scenario
    • 2.2.2 Rapid Growth Scenario
    • 2.2.3 Diminishing Growth Scenario

CHAPTER 3. GLOBAL REGENERATIVE MEDICINES MARKET OVERVIEW

  • 3.1 Market definition and scope
  • 3.2 Applications in organ regeneration
  • 3.3 Nanotechnology
    • 3.3.1 Nanoparticles
    • 3.3.2 Nanoscaffolds
  • 3.4 Materials for regenerative medicine
    • 3.4.1 Synthetic materials
    • 3.4.2 Biologically derived materials
    • 3.4.3 Genetically modified materials
  • 3.5 Key findings
    • 3.5.1 Top factors impacting regenerative medicine market
    • 3.5.2 Top winning strategies in the regenerative medicine market
    • 3.5.3 Top investment pockets
  • 3.6 Regulation and Reimbursement scenario
  • 3.7 Porter's five force analysis
    • 3.7.1 Limited number of suppliers and stringent government regulations lead to moderate bargaining power of supplier
    • 3.7.2 High cost of switching and differentiated products leads to lower bargaining power of buyers
    • 3.7.3 Inefficiency of substitutes leads to lower threat from substitute products
    • 3.7.4 High initial cost of investment leads to lower threats from new entrants
    • 3.7.5 High exit barrier and rapid pace of growth leads to moderate intensity of rivalry
  • 3.8 Value chain analysis
    • 3.8.1 Primary activities
    • 3.8.2 Supportive activities
  • 3.9 Clinical trials
  • 3.10 Drivers
    • 3.10.1 Advancements in stem cell technology
    • 3.10.2 Potential of nanotechnology
    • 3.10.3 Increasing incidences of chronic Diseases and trauma injuries
  • 3.11 Restraints
    • 3.11.1 Stringent regulatory policies and ethical issues
    • 3.11.2 Expensive treatment
  • 3.12 Opportunities
    • 3.12.1 Application of stem cells
    • 3.12.2 Market in emerging nations

CHAPTER 4. GLOBAL REGENERATIVE MEDICINE MARKET BY TECHNOLOGIES

  • 4.1 Small Molecules and Biologics
    • 4.1.1 Key market trends
    • 4.1.2 Competitive scenario
    • 4.1.3 Key growth factors and opportunities
    • 4.1.4 Market size & forecast
  • 4.2 Gene Therapy
    • 4.2.1 Key market trends
    • 4.2.2 Competitive scenario
    • 4.2.3 Key growth factors and opportunities
    • 4.2.4 Market size & forecast
  • 4.3 Cell Therapy
    • 4.3.1 Key market trends
    • 4.3.2 Competitive scenario
    • 4.3.3 Key growth factors and opportunities
    • 4.3.4 Market size & forecast

CHAPTER 5. GLOBAL REGENERATIVE MEDICINE MARKET BY APPLICATIONS

  • 5.1 Dermatology
  • 5.2 Cardiovascular Disorders
  • 5.3 Central Nervous System (CNS)
  • 5.4 Orthopedic
  • 5.5 Dental
  • 5.6 Others
    • 5.6.1 Autoimmune Diseases
    • 5.6.2 Muscle regeneration
    • 5.6.3 Ocular Diseases
    • 5.6.4 Internal organ regeneration

CHAPTER 6. GLOBAL REGENERATIVE MEDICINES MARKET BY GEOGRAPHY

  • 6.1 North America
    • 6.1.1 Key market trends
    • 6.1.2 Competitive scenario
    • 6.1.3 Market size & forecast
    • 6.1.4 Key growth factors and opportunities
  • 6.2 Europe
    • 6.2.1 Key market trends
    • 6.2.2 Competitive scenario
    • 6.2.3 Key growth factors and opportunities
    • 6.2.4 Market size & forecast
  • 6.3 Asia pacific
    • 6.3.1 Key market trends
    • 6.3.2 Competitive scenario
    • 6.3.3 Key growth factors and opportunities
    • 6.3.4 Market size & forecast
  • 6.4 LAMEA
    • 6.4.1 Key market trends
    • 6.4.2 Competitive scenario
    • 6.4.3 Key growth factors and opportunities
    • 6.4.4 Market size & forecast

CHAPTER 7. COMPANY PROFILES

  • 7.1 Shire Pharmaceuticals
    • 7.1.1 Company overview
    • 7.1.2 Company snapshot
    • 7.1.3 Business performance
    • 7.1.4 Strategic moves and developments
      • 7.1.4.1 Primary Strategies: Agreement
      • 7.1.4.2 Secondary Strategies: Acquisition
    • 7.1.5 SWOT Analysis of Shire Pharmaceuticals
  • 7.2 Advanced Cell Technology, Inc
    • 7.2.1 Company overview
    • 7.2.2 Company snapshot
    • 7.2.3 Business performance
    • 7.2.4 Strategic moves and developments
      • 7.2.4.1 Strategies: APPROVAL
    • 7.2.5 SWOT Analysis of Advanced Cell Technology
  • 7.3 Genzyme
    • 7.3.1 Company overview
    • 7.3.2 Company snapshot
    • 7.3.3 Business performance
    • 7.3.4 Strategic moves and developments
      • 7.3.4.1 Strategies:Approval
    • 7.3.5 SWOT Analysis of Genzyme
  • 7.4 Athersys, Inc.
    • 7.4.1 Company overview
    • 7.4.2 Company snapshot
    • 7.4.3 Business performance
    • 7.4.4 Strategic moves and developments
      • 7.4.4.1 Strategies
    • 7.4.5 SWOT Analysis of Athersys, Inc.
  • 7.5 Kinetic Concepts, Inc.
    • 7.5.1 Company overview
    • 7.5.2 Company snapshot
    • 7.5.3 Business performance
    • 7.5.4 Strategic moves and developments
      • 7.5.4.1 Strategies
    • 7.5.5 SWOT Analysis of Kinetic Concepts Inc.
  • 7.6 NuVasive Inc.
    • 7.6.1 Company overview
    • 7.6.2 Company snapshot
    • 7.6.3 Business performance
    • 7.6.4 Strategic moves and developments
      • 7.6.4.1 Strategies
    • 7.6.5 SWOT Analysis of NuVasive, Inc.
  • 7.7 Stem cells, Inc.
    • 7.7.1 Company overview
    • 7.7.2 Company snapshot
    • 7.7.3 Strategic moves and developments
      • 7.7.3.1 Primary Strategies: Approval
      • 7.7.3.2 Secondary strategies
    • 7.7.4 SWOT Analysis of Stem Cells, Inc.
  • 7.8 Cytori Therapeutics, Inc.
    • 7.8.1 Company overview
    • 7.8.2 Company snapshot
    • 7.8.3 Business performance
    • 7.8.4 Strategic moves and developments
      • 7.8.4.1 Strategies
    • 7.8.5 SWOT Analysis of Cytori Therapeutics, Inc.
  • 7.9 Cytomedix Inc.
    • 7.9.1 Company overview
    • 7.9.2 Company snapshot
    • 7.9.3 Strategic moves and developments
      • 7.9.3.1 strategies
    • 7.9.4 SWOT Analysis of Cytomedix Inc.
  • 7.10 Mesoblast Ltd.
    • 7.10.1 Company overview
    • 7.10.2 Company snapshot
    • 7.10.3 Strategic moves and developments
      • 7.10.3.1 strategies
    • 7.10.4 SWOT Analysis of Mesoblast Ltd.

List of Tables

Table 1 Regenerative medicine market, by geography 2013-2020 ($million)

Table 2 Global regenerative medicine market by geography, moderate case 2020-2025 ($million)

Table 3 Global regenerative medicine market by geography, rapid case 2020-2025 ($million)

Table 4 Global regenerative medicine market by geography, diminishing case 2020-2025 ($million)

Table 5 Synthetic materials, applications and its trade names

Table 6 Global regenerative medicine market revenue, by technology 2013-2020 ($million)

Table 7 Global small molecules and biologics regenerative technology market, by geography 2013-2020 ($million)

Table 8 Global gene therapy regenerative technology market, by geography 2013-2020 ($million)

Table 9 Commercialized cell therapy products (2013)

Table 10 Global cell therapy regenerative technology market, by geography 2013-2020 ($million)

Table 12 Global regenerative medicine market revenue, by application 2013-2020 ($million)

Table 13 Global dermatology regenerative medicines application market, by geography 2013-2020 ($million)

Table 14 Global cardiovascular regenerative medicines application market, by geography 2013-2020

Table 15 Global CNS regenerative medicine application market, by geography 2013-2020 ($million)

Table 16 Global orthopedic regenerative medicine application market, by geography 2013-2020 ($million)

Table 17 Global dental regenerative medicine application market, by geography 2013-2020 ($million)

Table 18 Global other regenerative medicine application market, by geography 2013-2020 ($million)

Table 19 Regenerative medicine market, by geography 2013-2020 ($million)

Table 20 North America regenerative medicine market, by application 2013-2020 ($million)

Table 21 Europe regenerative medicine market, by application 2013-2020 ($million)

Table 22 Asia Pacific regenerative medicine market, by application 2013-2020 ($million)

Table 23 LAMEA regenerative medicine market, by application 2013-2020 ($million)

Table 24 Shire Pharmaceuticals business snapshot

Table 25 Advanced Cell Technologies business snapshot

Table 26 Genzyme business snapshot

Table 27 Athersys, Inc. business snapshot

Table 28 Kinetic Concepts, INC. business snapshot

Table 29 Nuvasive, Inc. business snapshot

Table 30 Stem Cell, Inc. business snapshot

Table 31 Cytori Therapeutics, Inc. business snapshot

Table 32 Cytomedix, Inc. business snapshot

Table 33 Mesoblast Ltd. business snapshot

List of Figures

Fig. 1 Top factors impacting regenerative medicine market (2013-2020)

Fig. 2 Top winning strategies of regenerative medicine market (2011-2014)

Fig. 3 Top wining strategies by subtype of developments

Fig. 4 Top investment pockets in regenerative medicine applications market

Fig. 5 Porter's five force analysis

Fig. 6 Value chain analysis for regenerative medicine market

Fig. 7 The biologics market

Fig. 8 Commercialization of products as per applications (2013)

Fig. 9 SWOT analysis of shire pharmaceuticals

Fig. 10 SWOT analysis of advanced cell technology

Fig. 11 SWOT analysis of Genzyme

Fig. 12 SWOT analysis of Life Technologies

Fig. 13 SWOT analysis of Kinetic Concepts, Inc.

Fig. 14 SWOT analysis of Nuvasive, Inc.

Fig. 15 SWOT analysis of Stem Cells Inc.

Fig. 16 SWOT analysis of Cytori Therapeutics, Inc.

Fig. 17 SWOT analysis of Cytomedix, Inc.

Fig. 18 SWOT analysis of Mesoblast Ltd.

Back to Top